307 related articles for article (PubMed ID: 22336530)
1. Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial.
Kim JW; Chung J; Choi SH; Jang HJ; Hong SB; Lim CM; Koh Y
Crit Care; 2012 Feb; 16(1):R28. PubMed ID: 22336530
[TBL] [Abstract][Full Text] [Related]
2. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
West M; Boulanger BR; Fogarty C; Tennenberg A; Wiesinger B; Oross M; Wu SC; Fowler C; Morgan N; Kahn JB
Clin Ther; 2003 Feb; 25(2):485-506. PubMed ID: 12749509
[TBL] [Abstract][Full Text] [Related]
3. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia.
Joung MK; Lee JA; Moon SY; Cheong HS; Joo EJ; Ha YE; Sohn KM; Chung SM; Suh GY; Chung DR; Song JH; Peck KR
Crit Care; 2011; 15(2):R79. PubMed ID: 21366903
[TBL] [Abstract][Full Text] [Related]
4. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms.
Leroy O; d'Escrivan T; Devos P; Dubreuil L; Kipnis E; Georges H
Infection; 2005 Jun; 33(3):129-35. PubMed ID: 15940413
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
Youssif E; Aseeri M; Khoshhal S
J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
[TBL] [Abstract][Full Text] [Related]
6. Outcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia.
Cowley MC; Ritchie DJ; Hampton N; Kollef MH; Micek ST
Chest; 2019 Jan; 155(1):53-59. PubMed ID: 30621854
[TBL] [Abstract][Full Text] [Related]
7. Development of antibiotic treatment algorithms based on local ecology and respiratory surveillance cultures to restrict the use of broad-spectrum antimicrobial drugs in the treatment of hospital-acquired pneumonia in the intensive care unit: a retrospective analysis.
De Bus L; Saerens L; Gadeyne B; Boelens J; Claeys G; De Waele JJ; Benoit DD; Decruyenaere J; Depuydt PO
Crit Care; 2014 Jul; 18(4):R152. PubMed ID: 25030270
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
Ramirez J; Dartois N; Gandjini H; Yan JL; Korth-Bradley J; McGovern PC
Antimicrob Agents Chemother; 2013 Apr; 57(4):1756-62. PubMed ID: 23357775
[TBL] [Abstract][Full Text] [Related]
9. Imipenem-cilastatin. A new dimension.
S Afr Med J; 1988 Nov; 74(9 Suppl):1-8. PubMed ID: 3187839
[TBL] [Abstract][Full Text] [Related]
10. Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia.
Hibbard ML; Kopelman TR; O'Neill PJ; Maly TJ; Matthews MR; Cox JC; Vail SJ; Quan AN; Drachman DA
Surg Infect (Larchmt); 2010 Oct; 11(5):427-32. PubMed ID: 20818984
[TBL] [Abstract][Full Text] [Related]
11. Imipenem/cilastatin in the treatment of severe nosocomial pneumonia.
Potgieter PD; Linton DM; Forder AA; Plumb H
S Afr Med J; 1988 Oct; 74(8):390-2. PubMed ID: 3187816
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
Sakka SG; Glauner AK; Bulitta JB; Kinzig-Schippers M; Pfister W; Drusano GL; Sörgel F
Antimicrob Agents Chemother; 2007 Sep; 51(9):3304-10. PubMed ID: 17620371
[TBL] [Abstract][Full Text] [Related]
13. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia.
Jung YJ; Koh Y; Hong SB; Chung JW; Ho Choi S; Kim NJ; Kim MN; Choi IS; Han SY; Kim WD; Yun SC; Lim CM
Crit Care Med; 2010 Jan; 38(1):175-80. PubMed ID: 20050336
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
15. Early-onset pneumonia after liver transplantation: microbiological findings and therapeutic consequences.
Weiss E; Dahmani S; Bert F; Janny S; Sommacale D; Dondero F; Francoz C; Belghiti J; Mantz J; Paugam-Burtz C
Liver Transpl; 2010 Oct; 16(10):1178-85. PubMed ID: 20879016
[TBL] [Abstract][Full Text] [Related]
16. Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime.
Ho A; Leung R; Lai CK; Chan TH; Chan CH
Respiration; 1997; 64(3):224-8. PubMed ID: 9154675
[TBL] [Abstract][Full Text] [Related]
17. Locally derived versus guideline-based approach to treatment of hospital-acquired pneumonia in the trauma intensive care unit.
Becher RD; Hoth JJ; Rebo JJ; Kendall JL; Miller PR
Surg Infect (Larchmt); 2012 Dec; 13(6):352-9. PubMed ID: 23268613
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
Caldwell JW; Singh S; Johnson RH
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583
[TBL] [Abstract][Full Text] [Related]
19. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?
Eachempati SR; Hydo LJ; Shou J; Barie PS
J Trauma; 2009 May; 66(5):1343-8. PubMed ID: 19430237
[TBL] [Abstract][Full Text] [Related]
20. De-escalation versus continuation of empirical antimicrobial therapy in community-acquired pneumonia.
Yamana H; Matsui H; Tagami T; Hirashima J; Fushimi K; Yasunaga H
J Infect; 2016 Oct; 73(4):314-25. PubMed ID: 27394401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
